基因多态性对华法林抗凝治疗剂量影响的研究进展

摘要/Abstract

摘要： 华法林是临床上使用最广泛的香豆素类口服抗凝药，主要用于预防和治疗血栓栓塞性疾病。华法林疗效显著、口服吸收快、价格便宜，但治疗窗窄、个体差异大。华法林的个体差异受多种因素影响，其中遗传基因多态性是主要影响因素。本文综述了CYP2C9、VKORC1、CYP4F2、APOE、GGCX、EPHX1基因多态性对华法林抗凝治疗剂量影响的研究进展，以期为华法林的个体化用药提供依据。

关键词: font-size:medium, ">华法林；基因多态性；维持剂量；综述

Abstract: Warfarin is a widely used coumarin oral anticoagulant in clinical practice， which is mainly used to prevent and treat vascular embolism diseases.Warfarin is effective， rapid oral absorption and cheap， but it has a narrow treatment window with large individual variabilities. Individual differences of warfarin are influenced by many factors， gene polymorphism is the major effect factor. This article summarizes the latest research of the relationship between anticoagulation dose of warfarin and CYP2C9， VKORC1， CYP4F2， APOE， GGCX， EPHX1 gene polymorphism， in order to provide a basis for the clinical individualized medication of warfarin.

Key words: Warfarin, Gene polymorphism, Maintenance dose；Review

中图分类号:

杨清珵, 宋沧桑, 张阳, 张函舒. 基因多态性对华法林抗凝治疗剂量影响的研究进展[J]. 中国药物评价, 2021, 38(6): 531-535.

YANG Qing-cheng, SONG Cang-sang, ZHANG Yang, ZHANG Han-shu. Influence of Genetic Polymorphism on Anticoagulation Dosage of Warfarin[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2021, 38(6): 531-535.

参考文献

[1]《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 2018， 98(36): 2861-2885.
     [2]Jack A， Jack H， Leon P， et al. The Pharmacology and Management of the Vitamin K Antagonists[J]. Chest， 2004， 126(3): 205-223.
     [3]Flora DR， Rettie AE， Brundage RC， et al. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites[J]. J Clin Pharmacol， 2017， 57(3): 382-393.
     [4]Bi YA， Lin J， Mathialagan S， et al. Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation[J]. Mol Pharm， 2018， 15(3): 1284-1295.
     [5]National Center for Biotechnology Information Search database， https://www.ncbi.nlm.nih.gov/gene.
     [6]Mak M， Lam C， Pineda SJ， et al. Pharmacogenetics of Warfarin in a Diverse Patient Population[J]. J Cardiovasc Pharmacol Ther， 2019， 24(6): 521-533.
     [7]Qayyum A， Najmi MH， Mansoor Q， et al. Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population[J]. Clin Appl Thromb Hemost， 2017， 23(7): 800-806.
     [8]Khaleqsefat E， Khalaj Kondori M， Jabbarpour Bonyadi M， et al. Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9[J]. Hippokratia， 2017， 21(21): 93-96.
     [9]Fereidouni M， Moossavi M， Kazemi T， et al. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city， Iran[J]. J Cell Biochem， 2019， 120(6): 9588-9593.
     [10]Wang D， Dai D， Wu H， et al. Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation[J]. Pharmacogenomics， 2020， 21(14):1021-1031.
     [11]Bader L， Mahfouz A， Kasem M， et al. The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population[J]. Pharmacogenomics J， 2020， 20(2): 277-284.
     [12]Liu R， Cao J， Zhang Q， et al. Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement[J]. Medicine (Baltimore)， 2017， 96(2): e5658.
     [13]Takeuchi M， Kobayashi T， Biss T， et al. CYP2C9， VKORC1， and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis[J]. Pharmacogenomics J， 2020， 20(2): 306-319.
     [14]Zhang J， Tian L， Huang J， et al. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis[J]. Cardiovasc Ther， 2017， 35(1): 26-32.
     [15]Asiimwe IG， Zhang EJ， Osanlou R， et al. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis[J]. Clin Pharmacol Ther， 2020， 107(6): 1420-1433.
     [16]Xu Q， Zhang S， Wu C， et al. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients[J]. J Cardiovasc Pharmacol， 2021， 78(1): e105-e111.
     [17]Kocael A， Eronat AP， Tuzuner MB， et al. Interpretation of the effect of CYP2C9， VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey[J]. Mol Biol Rep， 2019， 46(2): 1825-1833.
     [18]Soltani Banavandi MJ and Satarzadeh N. Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province[J]. Pharmacogenomics J， 2020， 20(4): 574-578.
     [19]Li J， Kim M， Song K， et al. Impact of VKORC1， CYP2C9， and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters[J]. American Journal of Therapeutics， 2021， 28(4):e461-e468.
     [20]Li J， Yang W， Xie Z， et al. Impact of VKORC1， CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation[J]. BMC Cardiovasc Disord， 2018， 18(1): 96.
     [21]Johnson JA， Caudle KE， Gong L， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update[J]. Clin Pharmacol Ther， 2017， 102(3): 397-404.
     [22]Yang D， Kuang H， Zhou Y， et al. Height， VKORC1 1173， and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China[J]. Pediatr Cardiol， 2019， 40(1): 29-37.
     [23]Cho EH， Lee K， Yang M， et al. Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With VKORC1 1173C[J]. Ann Lab Med， 2020， 40(3): 216-223.
     [24]Al-Mahayri ZN， Al Jaibeji HS， Saab Y， et al. VKORC1 variants as significant predictors of warfarin dose in Emiratis[J]. Pharmgenomics Pers Med， 2019， 12: 47-57.
     [25]Dilge Taskin B， Kula S， Ergun MA， et al. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population[J]. Anatol J Cardiol， 2016， 16(10): 791-796.
     [26]Kabalak PA， Savas I， Akar N， et al. Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism[J]. Pharmacogenomics J， 2018， 18(5): 646-651.
     [27]Park JW， Kim KA and Park JY. Effects of Ketoconazole， a CYP4F2 Inhibitor， and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1[J]. J Clin Pharmacol， 2019， 59(11): 1453-1461.
     [28]Hirai K， Yamada Y， Hayashi H， et al. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy[J]. Thromb Res， 2015， 135(5): 861-866.
     [29]Khosropanaha S， Farajib S， Habibia H， et al. Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients[J]. Iran J Pharm Res， 2017， 16(3): 1238-1246.
     [30]Al-Eitan LN， Almasri AY， Alnaamneh AH， et al. Influence of CYP4F2， ApoE， and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan[J]. Int J Med Sci， 2021， 18(3): 826-834.
     [31]Zhang J， Chen Z，Chen C. Impact of CYP2C9， VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis[J]. Meta Gene， 2016， 9:197-209.
     [32]Zhang JE， Klein K， Jorgensen AL， et al. Effect of Genetic Variability in the CYP4F2， CYP4F11， and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response[J]. Front Pharmacol， 2017， 8: 323.
     [33]Yu WY， Sun X， Wadelius M， et al. Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis[J]. Cardiovasc Ther， 2016， 34(5): 297-307.
     [34]He S， Zhang H， Cao Y， et al. Association between apolipoprotein E genotype and warfarin response during initial anticoagulation[J]. Biomed Pharmacother， 2018， 101: 251-256.
     [35]Wenyan L， Ping Z， Liwen C， et al. Impact of CYP2C9， VKORC1， ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients[J]. Pharmacogenomics J， 2020， 21(2):101-110.
     [36]Rafieea S， Rajabibazla M， Meshkanic R， et al. Association of Warfarin Therapy with APOE and VKORC1 GenesPolymorphism in Iranian Population[J]. Iran J Pharm Res， 2017， 16(3): 1230-1237.
     [37]Bryk AH， Wypasek E， Plens K， et al. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms[J]. Vascul Pharmacol， 2018， 106: 22-27.
     [38]Tang XY， Zhang J， Peng J， et al. The association betweenGGCX， miR-133genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement[J]. Journal of Clinical Pharmacy and Therapeutics， 2017， 42(4): 438-445.
     [39]Wakamiya T， Hokosaki T， Tsujimoto S， et al. Effect of VKORC1， CYP2C9， CFP4F2， and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients[J]. Mol Diagn Ther， 2016， 20(4): 393-400.
     [40]Jiang NX， Xu YH， Xia JW， et al. Impact of GGCX polymorphisms on warfarin dose requirements in atrial fibrillation patients[J]. Turk J Med Sci， 2017， 47(4): 1239-1246.
     [41]Gaikwad T， Ghosh K， Avery P， et al. Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients[J]. Clin Appl Thromb Hemost， 2018， 24(2): 353-359.
     [42]Chung JE， Lee KE， Chang BC， et al. Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses[J]. Gene， 2018， 641: 68-73.
     [43]Lee MM，Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population.[J]. Pharmacogenomics， 2009， 10(12): 1905-1913.
     [44]Liu HQ， Zhang CP， Zhang CZ， et al. Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis[J]. Biomed Res Int， 2015， 2015: 564149.
     [45]Xianliang L， Hao C， Le N， et al. Effects of EPHX1 rs2260863 polymorphisms on warfarin maintenance dose in very elderly， frail Han-Chinese population[J]. Pharmacogenomics， 2020， 21(12):863-870.
     [46]Chan SL， Thalamuthu A， Goh BC， et al. Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population[J]. Pharmacogenet Genomics， 2011， 21(1): 35-41.